Abstract: The present invention concerns a method for the preparation of molecular conjugates comprising immunoglobulins and biomarkers occurring in neoplastic diseases characterized by high levels of reproducibility.

Abstract: A peptide of formula (I) (H2N—X1—Thr—X2—CO)n—R  (I) where X1 and X2, different one another, are an amino acid residue of arginine or tyrosine in configuration L or D, wherein the hydroxy group of threonine and tyrosine and the guanidine moiety of arginine may be protected by a compound conventionally used in peptide chemistry for protecting the hydroxy group and the guanidine moiety, respectively, n is 1,2, 3 or 4, and R, when n is 2,3 or 4, is a group suitable for forming a dimer, trimer or tetramer, while, when n is 1, R is OH, a single amino acid residue, or a peptide chain contains up to 7 amino acid residues.

Abstract: The present invention relates to a pharmaceutical composition comprising a biologically effective amount of a peptide of formula (I) (H2N—X1—CO—Thr—NH—X2—CO)n—R  (I) where NH—X1—CO and NH—X2—CO which are different from one another, are residues of tyrosine or arginine, in L or D configuration, where the hydroxy group of threonine and the guanidine moiety of arginine may be protected by a group conventionally used in peptide chemistry for protecting the hydroxy group and the guanidine moiety, respectively, n is 2, 3, or 4, R is a group capable of forming a dimeric, trimeric, or tetrameric peptide, and a pharmaceutically acceptable inert carrier.

Abstract: Disclosed herein are uses of a recombinant protein as a receptor for a hepatitis virus. Also disclosed are a nucleic acid coding for the receptor, a vector comprising a nucleic acid encoding the receptor, a host cell transformed or transfected with the nucleic acid, and a new recombinant protein having the biological property to act as a receptor for a hepatitis virus and a transgenic animal expressing the recombinant protein.

Abstract: Use of a peptide compound of formula (H2N-X1-Thr-X2-CO)n-R  (I) wherein X1, X2, n and R have the meanings stated in the description for preparing a pharmaceutical composition useful in the treatment of Systemic Lupus Erythematosus.

Abstract: An improved antigenic peptide where the amino acid sequence is modified by replacing one or more amino acids with glycine.

Abstract: A peptide of formula (I) (H2N—X1—Thr—X2—CO)n—R  (I) where X1 and X2, different one another, are an amino acid residue of arginine or tyrosine in configuration L or D, wherein the hydroxy group of threonine and tyrosine and the guanidine moiety of arginine may be protected by a compound conventionally used in peptide chemistry for protecting the hydroxy group and the guanidine moiety, respectively, n is 1,2, 3 or 4, and R, when n is 2,3 or 4, is a group suitable for forming a dimer, trimer or tetramer, while, when n is 1, R is OH, a single amino acid residue, or a peptide chain containing up to 7 amino acid residues.

Abstract: An improved antigenic peptide where the amino acid sequence is modified by replacing one or more amino acids with glycine.

Abstract: A peptide of formula (I)(H.sub.2 N--X.sub.1 --Thr--X.sub.2 --CO).sub.n --R (I)whereX.sub.1 and X.sub.2, different one another, are an amino acid residue of arginine or tyrosine in configuration L or D, wherein the hydroxy group of threonine and tyrosine and the guanidine moiety of arginine may be protected by a compound conventionally used in peptide chemistry for protecting the hydroxy group and the guanidine moiety, respectively, n is 1, 2, 3 or 4, andR, when n is 2, 3 or 4, is a group suitable for forming a dimer, trimer or tetramer, while, when n is 1, R is OH, a single amino acid residue, or a peptide chain containing up to 7 amino acid residues.

Abstract: A computer-implemented method for designing at least one anti-peptide sequence having affinity for target peptide or a fragment thereof suitable for synthesizing peptides and micromolecules, assaying for a target peptides, purifying target peptides, and/or preventing proteolyis of a polypeptide includes identification of the members of the amino acid sequence of the target peptide and their anti-sense or hydropathically complementary amino acids and determining the moving average hydropathy for the target and anti-sense members. The resulting lowest hydropathy identifies the anti-sense amino acid sequence for the target peptide. The members of the target peptide amino acid sequence are obtained along with their member-specific hydropathic values with the hydropathic values summed as a moving average. Anti-sense or complementary amino acid members are identified from the moving average information to generate an array of anti-sense amino acid sequences.